FDA
-
-
-
-
-
-
-
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
-
-
-
-
-
-
-
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Iovance Biotherapeutics names Corleen Roche as chief financial officer
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Alerts Investors There Is an Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
328,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

